E. Mark Saad's Insider Trades & SAST Disclosures
E. Mark Saad's most recent trade in Axsome Therapeutics Inc was a trade of 1,494 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 21, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern E. Mark Saad.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 1,494 | 1,494 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2024 | 11,016 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. | 11 Sep 2024 | 11,016 | 21,018 (0%) | 0% | 3.7 | 40,429 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Sale of securities on an exchange or to another person at price $ 91.31 per share. | 11 Sep 2024 | 11,016 | 10,002 (0%) | 0% | 91.3 | 1,005,871 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 5,799 | 5,799 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | E. Mark Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 1,519 | 1,519 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 5,681 | 5,681 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 2,224 | 2,224 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 16,976 | 16,976 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 2,337 | 2,337 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Purchase of securities on an exchange or from another person at price $ 34.53 per share. | 17 Nov 2021 | 3,000 | 10,002 (0%) | 0% | 34.5 | 103,597 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Purchase of securities on an exchange or from another person at price $ 34.40 per share. | 17 Nov 2021 | 100 | 100 (0%) | 0% | 34.4 | 3,440 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Purchase of securities on an exchange or from another person at price $ 34.45 per share. | 17 Nov 2021 | 100 | 100 (0%) | 0% | 34.5 | 3,445 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Purchase of securities on an exchange or from another person at price $ 34.40 per share. | 17 Nov 2021 | 100 | 100 (0%) | 0% | 34.4 | 3,440 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 7,325 | 7,325 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2021 | 1,241 | 1,241 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges